Longevity Pipeline
Rejuvenate Bio
Gene therapy (FGF21, sTGFβR2, klotho); reprogramming · Heart failure, aging
IND-enablingPartial Epigenetic Reprogramming
Mechanism
Gene therapy (FGF21, sTGFβR2, klotho); reprogramming
Intervention class
AAV gene therapy
Indication
Heart failure, aging
Stage
IND-enabling
Evidence
animal
Funding
VC-backed
Backers
Various
Overview
Church-lab spinout. Combinatorial gene therapy reversed multiple aging phenotypes in mice; reported partial reprogramming extending lifespan in old mice. Moving toward cardiac indications first.
Technology
Rejuvenate Bio works in Partial Epigenetic Reprogramming — Rewinding a cell's biological age without erasing what it is.
Read the Partial Epigenetic Reprogramming brief →Related companies
Altos Labs
Partial epigenetic reprogramming
Retro Biosciences
Reprogramming, autophagy, plasma factors
Life Biosciences
Partial reprogramming (OSK via AAV)
NewLimit
Epigenetic reprogramming (factor discovery)
Turn Biotechnologies
mRNA epigenetic reprogramming
Shift Bioscience
Reprogramming w/o dedifferentiation
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.